Articles tagged with Lymphoma
A UK National Cancer Research Institute trial suggests that a PET scan after chemotherapy can identify patients who don't need additional radiotherapy, reducing late effects. The study found that 90.8% of patients without further treatment remained disease-free compared to 94.6% in the radiotherapy group.
Researchers identify JAK/STAT3 cell signaling pathway as driver of ALK-negative anaplastic large cell lymphoma (ALCL), a particularly aggressive form of non-Hodgkin's lymphoma. Compounds targeting this pathway show promise in inhibiting disease progression, offering new hope for effective treatments.
A committee of lymphoma experts identified key priority areas in infrastructure and research to advance treatments. The Roadmap for Discovery and Translation in Lymphoma outlines priorities to improve understanding of lymphoma biology across diverse subtypes.
A phase 3 trial shows that brentuximab vedotin significantly increases progression-free survival in adults with hard-to-treat Hodgkin lymphoma. The drug was found to be well-tolerated, with side effects including peripheral neuropathy and neutropenia.
The International Lymphoma Radiation Oncology Group (ILROG) has issued a guideline outlining the use of 3D computed tomography-based radiation therapy planning and volumetric image guidance to treat pediatric Hodgkin lymphoma. The guidelines aim to reduce radiation dose to normal tissue and decrease the risk of late side effects.
Researchers found a mutated region in human mantle cell lymphoma DNA that disables programmed cell death. Cells with this mutation grow uncontrollably, but a new therapy approach targets the ubiquitin ligase responsible for the defect.
Researchers present new advances in treating relapsed and treatment-resistant lymphoma, including targeted therapies and stem cell transplantation, to improve patient outcomes. These studies show promising results for patients with HIV-associated lymphoma, where traditional treatments have been limited.
A late-stage clinical trial demonstrated that brentuximab vedotin can improve progression-free survival and overall survival in patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplant. The study showed a 20% improvement in progression-free survival rate and high response rates among patients.
A £600,000 grant from Cancer Research UK will fund a research study investigating the efficacy of BTK inhibiting drugs in treating mantle cell lymphoma. The trial will compare these new drugs to standard chemotherapy and aim to improve life expectancy and quality of life for patients.
A promising anti-cancer approach targeting Malt1 protein's protease function in lymphoma cells may also cause destructive autoimmune inflammation when its other functions are preserved. Researchers discovered this unexpected side effect using an animal model, emphasizing the need for new alternatives to treat lymphomas.
Two patients with cardiac lymphoma presented with brain metastasis, highlighting the need for identifying prognostic factors that predict brain relapse. Cardiac lymphoma is a rare condition often overlooked due to its potential for central nervous system metastasis.
A recent study suggests a potential link between breast implants and ALCL, a rare form of cancer that can develop in the breast region around 10 years after surgery. The exact causes are unclear, but researchers believe an abnormal immune response may be to blame.
Researchers at the University of Leicester have developed a novel electronic system for diagnosing canine lymphoma in its early stages and monitoring remission after chemotherapy. The cLBT test detects biomarkers associated with the disease, offering improved diagnostic capabilities for veterinarians and pet owners.
A new study published in The Lancet Haematology found that PET-CT is more accurate than conventional CT scanning in measuring response to treatment and predicting survival in patients with follicular lymphoma. The findings suggest that PET-CT should be used routinely in clinical practice to improve patient outcomes.
Researchers found that HCV reactivation did not negatively impact overall survival for HIV+ patients diagnosed with lymphoma. In fact, the study suggests these patients can tolerate chemotherapy without adverse outcomes, paving the way for increased enrollment in cancer clinical trials.
Researchers at the Institut de recherches cliniques de Montréal have discovered how the immune system kills abnormal blood cells. The study found that EAT-2 and SAP molecules work together to activate natural killer cells, which play a crucial role in protecting against viruses and cancer cells.
Interim results show omitted radiotherapy associated with higher early relapse rates in stage I/II Hodgkin's lymphoma. The study found no significant differences in progression-free survival between standard and experimental treatment arms.
A new pill called idelalisib shows promise in treating relapsed leukemia and lymphoma patients, with a significant response rate of 72% for CLL patients. However, MCL patients experienced less favorable responses, highlighting the need for further research to improve this therapy.
A new treatment approach in radioimmunotherapy has shown a high overall response rate of 94.4% and complete response in 69.4% of patients with follicular lymphoma. Researchers have found the treatment to be feasible and safe with minimal side effects.
Researchers have identified twenty specific proteins secreted by primary effusion lymphoma cell lines, which may explain the cancer's peculiar behavior. These proteins are involved in inflammation, immune response, and cell growth, and their presence in tumor cells could lead to more personalized treatment approaches.
Walter and Eliza Hall Institute researchers discovered that lymphoma cells with high levels of MYC are sensitive to disabling protein MCL-1, making it a potential target for treating cancers driven by this common cancer-causing change in cells.
A study published in Europe's leading reproductive medicine journal found that freezing semen before cancer treatment can significantly increase the chances of fatherhood. Among 334 male survivors who wanted to have children, those with frozen semen had a success rate of 62% compared to 21% without it.
Thomas Kipps, MD, PhD, receives a 5-year, $6.25 million grant from The Leukemia & Lymphoma Society to support research on chronic lymphocytic leukemia (CLL). The grant aims to identify potential new therapies that target identified pathways supporting leukemia-cell survival.
Pomalidomide shows promise in treating CNS lymphoma by improving survival and suppressing tumor growth. The clinical trial is now open at Mayo Clinic's three campuses.
Researchers created a stratified risk score to predict patient prognosis, finding that age, race, and stage of cancer significantly impact survival rates. The score separates patients into groups with varying 5-year relative survival rates, aiding doctors and researchers in designing treatment strategies.
Patients with celiac disease who have persistent intestine damage are at a higher risk of developing lymphoma compared to those whose intestines have healed, according to new research. The study found that the risk of lymphoma is significantly lower in patients with healed intestines, approaching that of the general population.
A new study found that regions near petroleum refineries and manufacturing plants releasing benzene have significantly higher non-Hodgkin lymphoma incidence rates. The risk of the disease decreases with increasing distance to these facilities.
Researchers developed a new treatment combining chemotherapy and radioimmunotherapy, which showed significant improvement in survival rates without recurrence. Patients who received this treatment had a 64% chance of survival and a 100% chance of survival at two-year follow-up.
Researchers at Johns Hopkins Medicine have developed a novel approach to sorting out cancer-causing genetic mutations in cancer cells. By testing proteins produced by genes with random mutations, they created a catalog of mutants with cancer-promoting potential. This could lead to more personalized treatment strategies for patients.
Researchers found that elevated galectin-1 levels correlate with tumor burden and adverse clinical characteristics in newly diagnosed Hodgkin lymphoma patients. The study suggests using galectin-1 as a biomarker to predict patient outcomes and inform treatment decisions.
Researchers have identified a key pathway called the Unfolded Protein Response (UPR) that helps tumor cells escape programmed cell death during lymphoma development. Inhibiting this pathway could lead to new blood cancer treatments.
Researchers discovered that inhibiting PDGFRB can prevent growth of this type of tumour, extending survival in mice and a human patient. The study found that imatinib treatment significantly improved the patient's prognosis.
Transplant recipients and lymphoma patients are at higher risk of developing melanoma, which can be fatal if not detected early. They should be aware of their skin changes and consult a dermatologist regularly.
A University of Rochester Medical Center study challenges traditional treatment guidelines for early-stage follicular lymphoma, concluding that six different therapies can bring remission. Careful patient staging is key to predicting prognosis and superior progression-free survival.
Researchers at MDC Berlin-Buch have identified a critical enzyme, PI3K, that enables c-MYC to transform B lymphocytes into malignant cells. This finding may lead to effective treatments by inhibiting the PI3K signaling pathway.
Researchers found tristetraprolin (TTP/ZFP36) to be a tumor suppressor that impairs lymphoma development and maintenance. The study's findings suggest TTP could be a key target for treating cancers with MYC involvement, including relapsed and refractory tumors.
Researchers at the University of York are launching a major study to improve survival rates for myeloma and lymphoma patients through earlier diagnosis. The study aims to develop an evidence base that could reduce time-to-diagnosis in patients with these cancers, ultimately saving thousands of lives.
Researchers found that viral lytic replication impairs the effectiveness of Nutlin-3, a targeted therapy for KSHV-induced lymphomas. The study suggests reactivating p53 as a selective treatment modality.
A study by Dr. Andreas Engert and colleagues found that six cycles of BEACOPPescalated chemotherapy followed by radiotherapy are more effective in treating advanced Hodgkin's lymphoma with fewer treatment-related events. This approach also reduces toxicity compared to the standard eight-cycle regimen.
Blood cancers in pregnancy can lead to increased risk of blood clots and health complications for the mother. Termination is recommended at early stages, while cancer therapy is possible later. Progesterone-only contraceptives are considered safe for patients in long-term remission.
A systematic review and meta-analysis of randomized control trials found no improvement in overall survival for adult patients with advanced follicular lymphoma who received high-dose chemotherapy and ASCT compared to conventional-dose chemotherapy alone. The study concluded that HDC-ASCT is not effective as a primary treatment option.
A new PET technique using FLT-PET has shown highly sensitive imaging for patients with mantle cell lymphoma, a relatively rare and devastating blood cancer. The study found that all cancerous lesions were very highly visible using FLT-PET, providing a powerful biomarker for MCL.
Researchers sequenced DNA from two sisters with follicular lymphoma and found identical BCL2/IGH rearrangements. The study identified 15 mutations that were present in both lymphomas, indicating a donor-recipient transmission of cancer-causing genetic material.
A randomized Phase III study found that repeated rituximab treatment at disease progression is just as effective as ongoing maintenance therapy in managing follicular lymphoma. The study suggests that an as-needed approach to treatment may be the preferred option for patients with low-tumor-burden FL, reducing healthcare costs and impr...
Researchers have discovered that cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide. This finding helps understand which patients may be more or less likely to respond to therapy, enabling the development of targeted treatments.
Researchers investigate how c-myc gene mutations interact with p53 and Bcl2 genes in Burkitt's lymphoma. The study shows that the nature of the second 'hit' determines immune response against developing tumours, with implications for cancer therapy.
Researchers have identified a new potential cancer drug targeting EPHA7, a tumor suppressor protein associated with follicular lymphoma. The discovery demonstrates the power of functional genomics in translating genetic insights into therapies.
Researchers at Fox Chase Cancer Center found that IMRT improved treatment outcomes for patients with extranodal lymphoma of the head and neck, with minimal side effects. The study showed high response rates and no severe dry mouth, relapses, or tissue abnormalities.
Researchers at the University of California, Davis have identified a protein that may play a key role in the development of lymphoma by inhibiting a tumor-suppressing gene. The study found that this protein, known as RNPC1, is frequently overactive in dog lymphomas and may contribute to the formation of cancerous cells.
Patients with aggressive non-Hodgkin lymphoma who receive early stem cell transplants have comparable survival rates to those who undergo chemotherapy alone. Researchers urge caution for patients with poor risk factors, recommending careful consultation with their physician.
A personalized vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with improved response in patients with a specific biological marker. The trial's findings have the potential to usher in a new age of cancer vaccines.
The incidence of idiopathic pulmonary fibrosis (IPF) is increasing rapidly in the UK, with estimated annual diagnoses of 5,000 new cases. Researchers found a significant rise in IPF-related deaths, with more people dying from IPF than from certain types of cancer.
A recent study by the RAND Corporation has confirmed a link between breast implants and anaplastic large cell lymphoma (ALCL), a rare type of immune system cancer. The disease takes a slow course and can be controlled by surgical removal of the implant and surrounding tissue.
Researchers at North Carolina State University used a genetic model of dogs to identify genes involved in human non-Hodgkin lymphoma. The study found that only a few genes were shared between dogs and humans, suggesting that the genetic changes associated with the cancer are much less complex in canines.
Researchers at Sbarro Health Research Organization have discovered a new mechanism for INK4/ARF protein inactivation in Burkitt's lymphoma. The study suggests that reactivating tumor suppressor genes p16 and p14 could lead to the inhibition of cell proliferation and induction of apoptosis, offering potential new treatment avenues.
Researchers developed computer-assisted diagnosis tools to grade Follicular Lymphoma samples more accurately and efficiently. The tools use high-resolution images and machine learning algorithms to identify malignant regions and classify disease grades, promising faster and more accurate diagnoses.
The PRIMA study found that rituximab-maintenance therapy significantly improved progression-free survival and response rates compared to no treatment in patients with follicular lymphoma. After 2 years, 71.5% of patients in the rituximab group achieved complete or unconfirmed complete response compared to 52.2% in the observation group.
The personalized vaccine is effective in preventing recurrence among certain follicular lymphoma patients with a specific protein on their tumor cells. The vaccine improves disease-free survival by nearly two years compared to placebo treatments.
Researchers present promising new treatment options for advanced asymptomatic follicular lymphoma, mantle cell lymphoma, and early Hodgkin disease. The study shows that upfront rituximab therapy can significantly prolong the time until a patient may require chemotherapy.
A new mutation in the B cell activating factor receptor (BAFF-R) has been identified as a potential contributor to non-Hodgkin's lymphoma. The mutation amplifies BAFF signaling, leading to increased B cell function and cancer progression.